Analysis of prothrombotic and vascular risk factors in patients with nonarteritic anterior ischemic optic neuropathy

Salomon, Ophira; Huna‐Baron, Ruth; Kurtz, Shimon; Steinberg, David M.; Moisseiev, Joseph; Rosenberg, Nurit; Yassur, Iftach; Vidne, Orit; Zivelin, Ariella; Gitel, Sanford N.; Davidson, Jacqueline; Ravid, B.; Seligsohn, Uri

doi:10.1016/s0161-6420(99)90159-8

Cited by 165 publications

(145 citation statements)

References 20 publications

Supporting

Mentioning

125

Contrasting

Unclassified

Order By: Relevance

“…For example, systemic hypertension has been documented in 34-49.4% of patients and diabetes mellitus in 5-25.3%. [29][30][31] Diabetes is associated with the development of NAION at a younger age in most series as well. Hyperlipidaemia is also a common finding in patients with NAION.…”

Section: Risk Factorsmentioning

confidence: 99%

Current concepts in the diagnosis, pathogenesis and management of nonarteritic anterior ischaemic optic neuropathy

Miller

Arnold

2014

Eye

184

139

View full text Add to dashboard Cite

Nonarteritic anterior ischaemic optic neuropathy (NAION) is the most common acute optic neuropathy in patients over the age of 50 and is the second most common cause of permanent optic nerve-related visual loss in adults after glaucoma. Patients typically present with acute, painless, unilateral loss of vision associated with a variable visual field defect, a relative afferent pupillary defect, a swollen, hyperaemic optic disc, and one or more flame-shaped peripapillary retinal haemorrhages. The pathogenesis of this condition is unknown, but it occurs primarily in patients with structurally small optic discs that have little or no cup and a variety of underlying vascular disorders that may or may not be known at the time of visual loss. There is no consistently beneficial medical or surgical treatment for the condition, but there are now animal models that allow testing of various potential therapies. About 40% of patients experience spontaneous improvement in visual acuity. Patients in whom NAION occurs in one eye have a 15-19% risk of developing a similar event in the opposite eye over the subsequent 5 years.

show abstract

Section: Risk Factorsmentioning

confidence: 99%

Current concepts in the diagnosis, pathogenesis and management of nonarteritic anterior ischaemic optic neuropathy

Miller

Arnold

2014

Eye

184

139

View full text Add to dashboard Cite

show abstract

“…While case control study done by Salomon et al [12] documented hypercholesterolemia to be a significant factor. Few more studies concluded association of smoking with NAION on basis of higher prevalence of NAION in smokers at younger age group as compared to nonsmokers.…”

Section: Etiologymentioning

confidence: 96%

Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)—A Brief Review

Patil¹,

Ganger²,

Saxena³

2016

OJOph

View full text Add to dashboard Cite

Ischemic optic neuropathies could be a result of inflammatory and non inflammatory small vessel disease and have been classified as arteritic and non-arteritic anterior ischemic optic neuropathy respectively. This review has been intended to elucidate the epidemiology, etiology, pathogenesis, clinical picture and management of NAION and the literature search was completed using the published data in Pubmed, Medline, and Ovid over the last five decades.

show abstract

“…Proposed systemic risk factors include vasculopathic conditions (i.e., diabetes, systemic hypertension, hypercholesterolemia, ischemic heart disease), nocturnal hypotension, obstructive sleep apnea syndrome, and hyperhomocysteinemia [13,23]. A number of prothrombotic polymorphisms (including protein C, protein S, antithrombin III, lupus anticoagulant, factor II G20210A prothrombin variant, methylenetetrahydrofolate reductase C677T and A1298C variants, factor V Leiden G1691A variant, platelet glycoprotein receptor IIIa (PIA2) allele, and apolipoprotein E (4) allele) have been investigated in NAION patients from different ethnic populations and have been found not to be associated with increased risk [28][29][30].…”

Section: Pathophysiologymentioning

confidence: 99%

Nonarteritic Anterior Ischemic Optic Neuropathy: An Update on Demographics, Clinical Presentation, Pathophysiology, Animal Models, Prognosis, and Treatment

Banik¹

2013

J Clin Exp Ophthalmol

View full text Add to dashboard Cite

Analysis of prothrombotic and vascular risk factors in patients with nonarteritic anterior ischemic optic neuropathy

Cited by 165 publications

References 20 publications

Current concepts in the diagnosis, pathogenesis and management of nonarteritic anterior ischaemic optic neuropathy

Current concepts in the diagnosis, pathogenesis and management of nonarteritic anterior ischaemic optic neuropathy

Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)—A Brief Review

Nonarteritic Anterior Ischemic Optic Neuropathy: An Update on Demographics, Clinical Presentation, Pathophysiology, Animal Models, Prognosis, and Treatment

Contact Info

Product

Resources

About